[Effects of voglibose, alpha-glucosidase inhibitor in treatment of impaired glucose tolerance].
Nakamura
Jiro
J
Division of Metabolic Diseases, Department of Internal Medicine, Nagoya University Graduate School of Medicine.
D000818:Animals; D050260:Carbohydrate Metabolism; D003924:Diabetes Mellitus, Type 2 / Q000209:etiology / Q000517:prevention & control*; D004791:Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D018149:Glucose Intolerance / Q000150:complications / Q000188:drug therapy*; D065089:Glycoside Hydrolase Inhibitors; D006801:Humans; D006943:Hyperglycemia / Q000150:complications / Q000188:drug therapy*; D007004:Hypoglycemic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D007294:Inositol / Q000031:analogs & derivatives* / Q000494:pharmacology* / Q000627:therapeutic use*; D007328:Insulin / Q000378:metabolism; D000078790:Insulin Secretion; D007408:Intestinal Absorption / Q000187:drug effects; D008297:Male; D008875:Middle Aged; D016032:Randomized Controlled Trials as Topic
D004791:Enzyme Inhibitors; D065089:Glycoside Hydrolase Inhibitors; D007004:Hypoglycemic Agents; D007328:Insulin; D007294:Inositol; C102817:voglibose